Eloxx reported results for the quarter ended June 30, 2026. The company completed a $66.0 million underwritten public offering and uplisted to the Nasdaq Capital Market, ending the quarter with $62.0 million in cash and no outstanding debt, which it expects will fund operations into mid-2028. The Phase 2b trial of exaluren in nonsense mutation Alport syndrome is expected to begin in the third quarter of 2026, and the European Commission granted orphan designation for exaluren in ADPKD in July 2026.